
APGE Stock Forecast & Price Target
APGE Analyst Ratings
Bulls say
Apogee Therapeutics is positioned for success due to its strong pipeline of optimized biologics targeting well-established mechanisms of action, its successful de-risking of therapeutic targets through advanced data generation, and its potential for dosing convenience in large revenue opportunities in the I&I market. The company's acquisition by ABBV further validates the interest in long half-life and combination assets in the I&I space. Despite risks related to clinical trial failure or regulatory approval, the successful closing of the deal with ABBV and continued advancements in its pipeline could lead to a significant increase in Apogee's stock value.
Bears say
Apogee Therapeutics is facing challenges with the potential safety issues of their long-acting OX40L antibody and the deprioritization of their IL-4Rα asset. The company has a potential fair value of $135/shr based on a 6x multiple to 2032-35E sales of each clinical-stage candidate in each target addressable indication, discounted back by a risk-adjusted discount rate. Despite having a peak revenue potential of $7B and significant market opportunities in I&I indications, there are concerns surrounding the company's sustainability and adherence to ethical practices.
This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
APGE Analyst Forecast & Price Prediction
Start investing in APGE
Order type
Buy in
Order amount
Est. shares
0 shares